within Pharmacolibrary.Drugs.ATC.R;

model R06AX18
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0,
    Cl             = 0.14333333333333334,
    adminDuration  = 600,
    adminMass      = 0.008,
    adminCount     = 1,
    Vd             = 0.065,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0105,
    Tlag           = 10.020000000000001
  );

  annotation(Documentation(
    info ="<html><body><p>Acrivastine is a second-generation non-sedating antihistamine used for the symptomatic relief of allergic conditions such as hay fever, urticaria, and other allergic rhinitis symptoms. It is commonly available in combination with pseudoephedrine and is approved for use in several countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult subjects after a single oral dose of 8 mg acrivastine.</p><h4>References</h4><ol><li>J W Slater, A D Zechnich, D G Haxby,Second-generation antihistamines: a comparative review.,Drugs,1999<a href='https://pubmed.ncbi.nlm.nih.gov/9951950/'>https://pubmed.ncbi.nlm.nih.gov/9951950/</a></li><li>R N Brogden, D McTavish,Acrivastine. A review of its pharmacological properties and therapeutic efficacy in allergic rhinitis, urticaria and related disorders.,Drugs,1991<a href='https://pubmed.ncbi.nlm.nih.gov/1715267/'>https://pubmed.ncbi.nlm.nih.gov/1715267/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end R06AX18;
